Treadwell-Announces-Initiation-Patient-Dosing-TWT-101-Phase

Treadwell Announces Initiation of Patient Dosing in TWT-101, a Phase 1/2 Study of HPK1 Inhibitor, CFI-402411, in Patients with Solid Tumors